Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 2019;393:2332–43.
Sawalha AH, Zhao M, Coit P, Lu Q. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 2020;215:108410.
Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 2020;79:1382–3.
Alia E, Grant-Kels JM. Does hydroxychloroquine combat COVID-19? A timeline of evidence. J Am Acad Dermatol 2020; 83: e33–4.
Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. New Eng J Med 2020; 383:517–25.
Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79: 667–8.
Yazdany J, Kim AHJ. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med 2020; 172:754–5.
Acknowledgments and disclosures
Acknowledgments: we would like to thank Biling Jiang, Yangxue Fu, Ganglin Xu, Xiaoping Miao, Chun Zhang, Rong Du, Wang xue, Li Qianru, Lou Yuchen, Wang bingbing, Sha shanshan, Su Xingyu, Song Zexing, Wang Yifei, Huang Qiuyi, Xia Yuting, Yang liu, Nie Wenjia, Liu Yan, Gao Lixie, Yin Taoyuan for their clinical follow-up support in this paper. Funding: This work was supported by HUST COVID-19 Rapid Response Call Program (2020kfyXGYJ056) and Hubei Provincial Emergency Science and Technology Program for COVID-19 (2020FCA037). Conflicts of interest: none. Ethics approval: the study was reviewed and approved by the Wuhan Union Hospital Ethics Committee (0064-1).
About this article
Cite this article
Wen, J., Suo, H., Zhang, Y. et al. Risk of COVID-19 infection among lupus erythematosus patients and rheumatoid arthritis patients: a retrospective study in Hubei, China. Eur J Dermatol 30, 751–753 (2020). https://doi.org/10.1684/ejd.2020.3926